Market research
0ZPN.F Zosano Pharma Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 2.97
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 2.97
About
About Zosano Pharma Corporation
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0ZPN.F discussion.
5 years, 5 months ago
Zosano Pharma Corporation is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.
From a valuation standpoint, the stock is 71.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 369.0.
Zosano Pharma Corporation's total revenue rose by inf% to $224K since the same quarter in the previous year.
Its net income has increased by 9.4% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.8% to $-7M since the same quarter in the previous year.
Based on the above factors, Zosano Pharma Corporation gets an overall score of 4/5.